Literature DB >> 24939818

Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?

Graham R Williams1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24939818     DOI： 10.1007/s40618-014-0110-9

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  33 in total

Review 1.  Thyroid hormone metabolism in skeletal development and adult bone maintenance.

Authors:  Julian A Waung; J H Duncan Bassett; Graham R Williams
Journal:  Trends Endocrinol Metab       Date:  2011-12-12       Impact factor: 12.015

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 3.  Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.

Authors:  Erik F Eriksen; Adolfo Díez-Pérez; Steven Boonen
Journal:  Bone       Date:  2013-10-09       Impact factor: 4.398

4.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

5.  Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.

Authors:  J Faber; A M Galløe
Journal:  Eur J Endocrinol       Date:  1994-04       Impact factor: 6.664

6.  The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat. Comparison between effects on tibiae and vertebrae.

Authors:  R Balena; A Markatos; M Gentile; P Masarachia; J G Seedor; G A Rodan; M Yamamoto
Journal:  Bone       Date:  1993 May-Jun       Impact factor: 4.398

7.  Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.

Authors:  D S Cooper; B Specker; M Ho; M Sperling; P W Ladenson; D S Ross; K B Ain; S T Bigos; J D Brierley; B R Haugen; I Klein; J Robbins; S I Sherman; T Taylor; H R Maxon
Journal:  Thyroid       Date:  1998-09       Impact factor: 6.568

8.  Use of disphosphonates in the treatment of osteoporosis in thyroidectomized patients on levothyroxin replacement therapy.

Authors:  P Panebianco; D Rosso; G Destro; R A Scarpinato; S Tropea; A Rizzo; M S Russo; M Motta; F Di Stefano; R Mazzarella; D Maugeri
Journal:  Arch Gerontol Geriatr       Date:  1997 Sep-Oct       Impact factor: 3.250

9.  Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.

Authors:  Annalisa Panico; Gelsy Arianna Lupoli; Francesco Fonderico; Francesca Marciello; Addolorata Martinelli; Roberta Assante; Giovanni Lupoli
Journal:  Thyroid       Date:  2009-05       Impact factor: 6.568

Review 10.  Risk of atrial fibrillation with use of oral and intravenous bisphosphonates.

Authors:  Abhishek Sharma; Andrew J Einstein; Ajay Vallakati; Armin Arbab-Zadeh; Marcella Donovan Walker; Debabrata Mukherjee; Peter Homel; Jeffrey S Borer; Edgar Lichstein
Journal:  Am J Cardiol       Date:  2014-03-15       Impact factor: 2.778
View more
  3 in total

Review 1.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

Review 2.  [Impact of thyroid diseases on bone].

Authors:  E Tsourdi; F Lademann; H Siggelkow
Journal:  Internist (Berl)       Date:  2018-07       Impact factor: 0.743

Review 3.  Thyroid diseases and bone health.

Authors:  G R Williams; J H D Bassett
Journal:  J Endocrinol Invest       Date:  2017-08-29       Impact factor: 4.256
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.